Wealth Enhancement Advisory Services
AKBA icon

Wealth Enhancement Advisory Services’s Akebia Therapeutics AKBA Stock Holding History

Wealth Enhancement Advisory Services’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$157K Buy
112,474
+93,740
+500% +$112K ﹤0.01% 3675
2026
Q1 		$25.9K Buy
+18,734
New +$25.7K ﹤0.01% 3485
2025
Q4 		– Sell
-16,226
Closed -$47.9K – 3651
2025
Q3 		$47.9K Buy
16,226
+42
+0.3% +$140 ﹤0.01% 3437
2025
Q2 		$58.6K Buy
+16,184
New +$44.5K ﹤0.01% 3209

Other funds holding AKBA

HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
CAMG
CWA Asset Management Group Naples, Florida $3.28B AUM 34.07% 1-Year Est. Return
MFG
Merit Financial Group Alpharetta, Georgia $16.4B AUM 25.17% 1-Year Est. Return
EWS
Eagle Wealth Strategies West Deptford, New Jersey $262M AUM 31.52% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
AWM
Activest Wealth Management Aventure, Florida $518M AUM 44.34% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return

Wealth Enhancement Advisory Services's AKBA Position: Q2 2026 in Review

Wealth Enhancement Advisory Services increased its Akebia Therapeutics (AKBA) stake by 500% in Q2 2026, buying an estimated $112K and bringing the position to 112,474 shares worth $157K. The position accounts for ﹤0.01% of the portfolio, ranked #3675.

Wealth Enhancement Advisory Services first reported a position in AKBA in Q2 2025 and has held it in 4 quarters since. 9 funds tracked by Wall St. Rank hold AKBA as of Q2 2026.

  • Wealth Enhancement Advisory Services held 112,474 shares of Akebia Therapeutics worth $157K as of Q2 2026.
  • Wealth Enhancement Advisory Services bought 93,740 Akebia Therapeutics shares in Q2 2026, an estimated $112K.
  • Akebia Therapeutics made up ﹤0.01% of Wealth Enhancement Advisory Services's portfolio in Q2 2026, its #3675 holding.
  • Wealth Enhancement Advisory Services first reported a position in Akebia Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • 9 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2026.

Based on Wealth Enhancement Advisory Services's 13F filing for Q2 2026, filed 15 Jul 2026.